Oramed Pharmaceuticals Inc. — Director's Dealing 2022

May 10, 2022

SEC Form 4
------------

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*				2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
Mayer Arie					ORMP ]							X Director			10% Owner
													Officer (give title		Other (specify
(Last) (First) (Middle) 16 MORAN STREET					3. Date of Earliest Transaction (Month/Day/Year) 11/01/2021							below)		below)
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)
KFAR SABA	L3		4428890									X		Form filed by One Reporting Person
												Person		Form filed by More than One Reporting
(City)		(State)	(Zip)
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
2. Transaction 1. Title of Security (Instr. 3) Date (Month/Day/Year)			2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially	Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
							Code	V	Amount	(A) or (D)	Price	Reported	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock 11/01/2021							S		3,000	D	\$25.6		0	D
			Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned		(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security	2. Conversion	3. Transaction Date	3A. Deemed Execution Date,	4. 5. Number Transaction of Code (Instr. Derivative			6. Date Exercisable and 7. Title and Expiration Date Amount of (Month/Day/Year) Securities				8. Price of Derivative	9. Number of derivative	10. Ownership	11. Nature of Indirect

Security (Instr. 3)	or Exercise Price of Derivative Security	(Month/Day/Year)	if any (Month/Day/Year)	Code (Instr. 8)		Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		(Month/Day/Year)		Securities Underlying Derivative Security (Instr. 3 and 4)		Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code V		(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

/s/ Arie Mayer 05/10/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.